The hydroxypropyl-β-cyclodextrin complexation of toltrazuril for enhancing bioavailability.
Li Zhang,Mengxi Liu,Chaocheng Lu,Dandan Ren,Guoqing Fan,Chang Liu,Mengjiao Liu,Gang Shu,Guangneng Peng,Zhixiang Yuan,Zhijun Zhong,Wei Zhang,Hualin Fu
DOI: https://doi.org/10.2147/DDDT.S157611
IF: 4.3188
2018-01-01
Drug Design Development and Therapy
Abstract:Introduction: Toltrazuril (Tol) is used to prevent and combat coccidiosis. However, its low aqueous solubility and poor oral bioavailability limit clinical application. Methods: To overcome the shortcomings, toltrazuril-hydroxypropyl-beta-cyclodextrin inclusion complex (Tol-HP-beta-CD) was prepared and characterized. The comparative plasma disposition kinetics of Tol was analyzed after a single orally administered dose of 10 mg/kg Tol or Tol-HP-beta-CD in rabbits. Solution-stirring method was selected to prepare the inclusion complex. Complex formation was characterized by thin-layer chromatography, Fourier transform infrared spectrophotometry, and H-1 nuclear magnetic resonance spectroscopy. In plasma profile, plasma samples were collected between 1 and 10 days following administration. Plasma Tol concentrations were determined by high-performance liquid chromatography. Results: In rabbit plasma, the time to peak concentration (T-max) of Tol-HP-beta-CD was shorter than that of Tol (12 h vs 24 h). C-max (19.92 +/- 1.02 mu g/mL) and area under the concentration-time curve (AUC0-infinity, 1,176.86 +/- 70.26 mg/L h) of the Tol-HP-beta-CD group significantly increased (p<0.01) than those of the Tol group (C-max, 8.02 +/- 1.04 mu g/mL; AUC0-infinity, 514.03 +/- 66.65 mg/L h). Conclusion: It can be concluded that the Tol-HP-beta-CD increased the aqueous solubility and enhanced the oral bioavailability in rabbits. Complexation with HP-beta-CD is a feasible way to prepare a rapidly absorbed and more bioavailable Tol oral product.